Hyloris Pharmaceuticals Announces Coverage of the Maximum Offering Size, including Increase Option and Over-Allotment, at the Midpoint of the Price Range of its Initial Public Offering on Euronext Brussels NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, SWITZERLAND, ISRAEL, JAPAN OR SOUTH AFRICA  This announcement does not constitute an...

Hyloris Pharmaceuticals Announces Intention to Launch an Initial Public Offering on Euronext Brussels This announcement does not constitute an offer to sell, or an invitation to offer or buy or subscribe for, securities. An investment in the offered shares involves substantial risks and uncertainties....